Status:
COMPLETED
A Systems Approach to Predict the Outcome of SARS-CoV-2 in the Population of a City; COVID-19
Lead Sponsor:
University Hospital, Basel, Switzerland
Collaborating Sponsors:
sciCORE University of Basel
Leonhard Med IT ETH Zurich
Conditions:
SARS Coronavirus (SARS-CoV-2) Infection
Eligibility:
All Genders
Brief Summary
This study is to gain critical knowledge to understand the factors influencing the outcome of a pandemic virus within the city of Basel.
Detailed Description
In order to evaluate the impact of the new SARS-CoV-2 this study analyzes the clinical outcomes of patients with a confirmed SARS-CoV-2 infection using a systems approach. The objective is to integrat...
Eligibility Criteria
Inclusion
- Study A: All patients being tested for SARS-CoV-2 at the University Hospital Basel (USB) and with residency in Basel (Basel-Stadt, Riehen, and Bettingen) will be included for clinical outcome evaluation. All age groups will be included. In addition, non-clinical data such as epidemiological and hospital associated data of all people living in Basel but not necessarily tested at the University Hospital Basel will be included
- Study B: Epidemiological data and serum and respiratory samples across all Age groups from people with residency in Basel (Basel-Stadt, Riehen, and Bettingen) with and without confirmed SARS-CoV-2 infection will be included
- Study C: SARS-CoV-2 viral genome analysis will be conducted from all patients tested positive for SARS-CoV-2 genome by NAT at the University Hospital Basel and living in Basel (Basel-Stadt, Riehen, and Bettingen). In addition, viral genome analysis will be conducted from all people tested positive for SARS-CoV-2 genome by NAT living in Basel by the mentioned study partners. All Age groups will be included.
- Patients with cleared SARS-CoV-2 infection coming for plasma donation will be included to describe immunological response after successfully cleared infection.
Exclusion
- documented refusal of the general consent or an available/known written or oral statement against Research
- People, who are tested at the USB, with residency outside of Basel (Basel-Stadt, Riehen, and Bettingen)
Key Trial Info
Start Date :
April 9 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 31 2022
Estimated Enrollment :
126586 Patients enrolled
Trial Details
Trial ID
NCT04351503
Start Date
April 9 2020
End Date
July 31 2022
Last Update
May 9 2024
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Viollier AG
Allschwil, Switzerland, 4123
2
University Hospital Basel
Basel, Switzerland, 4031
3
Biozentrum University of Basel
Basel, Switzerland, 4056
4
sciCore University of Basel
Basel, Switzerland, 4056